Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment–a review

KTK Lau, L Ng, JWH Wong, HHF Loong… - Reviews in Endocrine …, 2021 - Springer
Developed as an antidiabetic drug, recent evidence suggests that several sodium-glucose
co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit …
被引用次数：25 相关文章

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment-A Review

KTK Lau, L Ng, JWH Wong… - … in endocrine & …, 2021 - pubmed.ncbi.nlm.nih.gov
Developed as an antidiabetic drug, recent evidence suggests that several sodium-glucose
co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit …

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment-A Review.

KTK Lau, L Ng, JWH Wong, HHF Loong… - Reviews in Endocrine …, 2021 - europepmc.org
Developed as an antidiabetic drug, recent evidence suggests that several sodium-glucose
co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit …

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment–A Review

KTK Lau, L Ng, JWH Wong, HHF Loong… - Reviews in Endocrine & …, 2021 - hub.hku.hk
Developed as an antidiabetic drug, recent evidence suggests that several sodium-glucose
co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit …

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment–A Review

LK TK, L Ng, CW WL, LC Ho… - Reviews in Endocrine & …, 2021 - search.proquest.com
Developed as an antidiabetic drug, recent evidence suggests that several sodium-glucose
co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit …